Accelerating the Development of an AI-Driven Ecosystem for Innovative Drug R&D and Translation

加速构建人工智能驱动的创新药物研发与转化生态系统

SHANGHAI

上海

,

，

Nov. 9, 2026

2026年11月9日

/PRNewswire/ -- Sanyou Biopharmaceuticals Co., Ltd. ('Sanyou Bio') recently announced the completion of a Series C financing round worth nearly RMB 100 million. The round was exclusively funded by Zero2IPO Industry Investment, a fund managed by Zero2IPO Group.

/美通社/ -- 三友生物制药有限公司（“三友生物”）近日宣布完成近1亿元人民币的C轮融资。本轮融资由清科集团旗下的基金——清科产业投资独家注资。

This financing represents strong recognition from the capital markets of Sanyou Bio's technological capabilities, innovative drug R&D system, and future growth potential. It also marks a new stage in the company's development in innovative drug R&D and commercialization.

此次融资体现了资本市场对三友生物的技术实力、创新药研发体系及未来增长潜力的高度认可，也标志着公司在创新药研发与商业化进程中迈入全新阶段。

With the vision of becoming a front-runner in global innovative drug R&D, Sanyou Bio has built a world-leading AI-Super-Trillion Antibody Library (AI-STAL), an integrated wet-lab and dry-lab Sanyou AI-Drug Accelerator (SAI-DA), and Clicklinks, a collaborative innovation platform for original drug discovery and development.

秉承成为全球创新药物研发领跑者的愿景，三友生物构建了世界领先的人工智能超万亿抗体库（AI-STAL）、集成湿实验与干实验的三友人工智能药物加速平台（SAI-DA），以及专注于原创药物发现与开发的协同创新平台Clicklinks。

Driven by three interconnected pillars—innovation at the source, intelligent acceleration, and pipeline-driven development—the company is systematically addressing bottlenecks in early-stage drug discovery, connecting the entire preclinical R&D value chain, and joining forces with partners to build a new ecosystem for innovative drug development..

在源头创新、智能加速和管线驱动发展这三大相互关联的支柱推动下，公司正系统性地解决早期药物研发中的瓶颈问题，贯通临床前研发的全价值链，并与合作伙伴携手共建创新药物开发的新生态。

From technology platform development to innovation ecosystem building, and from enhancing R&D capabilities to advancing drug pipeline translation, Sanyou Bio is exploring new pathways to improve the efficiency of innovative drug R&D and enhance industrial value through a systematic, intelligent, and global development strategy. .

从技术平台开发到创新生态系统构建，从提升研发能力到推进药物管线转化，三友生物正通过系统化、智能化和全球化的发展战略，探索提高创新药研发效率、提升产业价值的新路径。

Previously, Sanyou Bio completed its Series A financing in May 2020, Series B financing in June 2021, and Series B+ financing in August 2022. The completion of this Series C financing marks another significant milestone in the company's development, bringing its total funding raised to nearly RMB 300 million..

此前，三友生物已于2020年5月完成A轮融资，2021年6月完成B轮融资，2022年8月完成B+轮融资。此次C轮融资的完成标志着公司发展历程中的又一重要里程碑，使其累计融资总额接近人民币3亿元。

Synergy Across Three Core Platforms: Building an AI-Driven Innovative Drug R&D System

三大核心平台协同：构建人工智能驱动的创新药物研发体系

In recent years, the deep integration of artificial intelligence and life sciences has been reshaping the technological pathways and industrial landscape of innovative drug development. Advancing innovative drug R&D requires not only continuous breakthroughs in the efficiency of early-stage molecular discovery, but also the integration of critical links spanning drug design, experimental validation, R&D advancement, and commercialization..

近年来，人工智能与生命科学的深度融合正在重塑创新药物研发的技术路径和产业格局。推进创新药物研发不仅需要在早期分子发现效率上持续取得突破，还需要整合涵盖药物设计、实验验证、研发推进以及商业化等关键环节。

In response to these industry needs, Sanyou Bio has progressively established a business model driven by AI technology, supported by intelligent R&D platforms, and guided by its innovative drug pipeline. This financing will further accelerate the development and refinement of this integrated system, supporting the company's evolution from providing innovative drug R&D services toward building pipeline-driven, platform-based, and systematic capabilities for drug innovation and translation..

为应对这些行业需求，三友生物逐步建立起以人工智能技术为驱动、以智能研发平台为支撑、以创新药管线为导向的商业模式。此次融资将进一步加速该一体化体系的开发与完善，支持公司从提供创新药研发服务向构建以管线为驱动、以平台为基础、系统化的药物创新与转化能力转型。

AI-STAL features a proprietary 11-trillion-scale molecular library, providing a powerful foundation for the discovery of novel molecules at the source of innovative drug development.

AI-STAL 拥有专有的11万亿规模分子库，为在创新药物研发的源头发现新型分子提供了强大基础。

SAI-DA integrates dozens of AI algorithms with wet-lab capabilities covering the entire preclinical R&D process, creating an integrated wet-lab and dry-lab drug development accelerator characterized by automation and intelligence.

SAI-DA 将数十种人工智能算法与覆盖临床前研发全流程的湿实验能力相结合，打造出一个以自动化和智能化为特征的干湿实验一体化药物研发加速器。

Clicklinks serves as an open innovation hub for original drug discovery, bringing together global innovation resources and industry partners to foster a collaborative ecosystem for innovative drug R&D.

Clicklinks 作为原创药物发现的开放创新枢纽，汇聚全球创新资源与产业合作伙伴，构建协同合作的创新药物研发生态系统。

Together, the three platforms form an integrated, end-to-end system spanning early-stage molecular discovery, R&D acceleration, and the translation of innovative discoveries into tangible outcomes.

这三大平台共同构成一个一体化的端到端系统，涵盖早期分子发现、研发加速以及将创新发现转化为切实成果的全过程。

From Platform Development to Pipeline-Driven Growth: Turning Innovative Achievements into Industrial Value

从平台开发到管道驱动增长：将创新成果转化为产业价值

Building on its platform capabilities, Sanyou Bio will further focus on pipeline-driven drug development and translation, accelerating the transformation of technological advantages into innovative achievements and industrial value.

依托其平台能力，三友生物将进一步聚焦于以研发管线驱动的药物开发与转化，加速将技术优势转化为创新成果和产业价值。

To date, the company has established partnerships with more than 2,000 pharmaceutical and biotechnology companies worldwide and completed more than 100 collaborative R&D projects, with over 10 innovative drug projects having entered clinical research. In addition, the company has completed 1,000+ drug discovery and stage-specific R&D projects, as well as deliveries of thousands of branded products..

迄今为止，公司已与全球2,000多家制药和生物技术公司建立合作伙伴关系，完成100多个合作研发项目，其中超过10个创新药项目已进入临床研究阶段。此外，公司还完成了1,000多个药物发现及分阶段研发项目，并交付了数千种品牌产品。

Looking ahead, Sanyou Bio will leverage its three core platforms, global partnership network, and accumulated R&D expertise to further strengthen its independent innovation capabilities and pipeline portfolio. Through platform synergy, project-driven development, and open collaboration, the company aims to improve overall efficiency throughout the drug development process, from early-stage research to downstream translation, and enable more innovative discoveries to realize their industrial value..

展望未来，三友生物将依托其三大核心平台、全球合作伙伴网络以及积累的研发专长，进一步强化自主创新能力和产品管线组合。通过平台协同、项目驱动开发和开放合作，公司旨在提升从早期研究到下游转化整个药物开发流程的整体效率，推动更多创新发现实现其产业价值。

Dr. Guojun Lang, Founder and CEO of Sanyou Bio, commented:  'Innovative drug development is a systematic undertaking that requires long-term investment, technological accumulation, and industrial collaboration. Sanyou Bio has always remained committed to its mission of 'To make it easy to develop new drugs worldwide.' Through technological innovation and the development of systematic capabilities, we aim to help the industry improve the efficiency of innovative drug R&D, lower barriers to innovation, and empower more partners in drug development.'.

三友生物创始人兼首席执行官郎国军博士表示：“创新药研发是一项系统工程，需要长期投入、技术积累和产业协作。三友生物始终秉持‘让全球新药研发更简单’的使命，通过技术创新和系统化能力建设，助力行业提升创新药研发效率，降低创新门槛，赋能更多药物开发合作伙伴。”

'This financing represents recognition of our technological achievements and strategic direction to date, while also providing important momentum as we move into our next stage of development. Going forward, we will continue to invest in the development of our three core platforms—AI-STAL, SAI-DA, and Clicklinks—leveraging AI to empower innovative drug R&D, enhancing R&D efficiency through platform synergy, and further focusing on pipeline-driven drug translation.

“此次融资既是对我们迄今为止技术成就和战略方向的认可，也为我们要进入的下一个发展阶段提供了重要动力。展望未来，我们将持续投入三大核心平台——AI-STAL、SAI-DA 和 Clicklinks 的开发，利用人工智能赋能创新药物研发，通过平台协同效应提升研发效率，并进一步聚焦于以管线驱动的药物转化。”

Our goal is to transform our technological strengths into innovative outcomes with genuine clinical and industrial value.'.

我们的目标是将技术优势转化为具有真正临床和产业价值的创新成果。

'We look forward to working hand in hand with partners around the world to accelerate innovative drug development and bring greater benefits to patients worldwide.'

“我们期待与全球合作伙伴携手合作，加速创新药物研发，为全世界患者带来更大福祉。”

Ms. Min Yang, Managing Partner of Zero2IPO Group and Managing Partner of Zero2IPO Industry Investment, commented: 'Innovative drug development is a field characterized by high technological barriers, deep professional expertise, and long-term value creation. As artificial intelligence and life sciences continue to converge, the industry is facing increasingly demanding requirements for efficient, intelligent, and systematic drug development capabilities.'.

清科集团管理合伙人、清科产业投资管理合伙人杨敏女士表示：“创新药研发是一个技术壁垒高、专业积淀深、注重长期价值创造的领域。随着人工智能与生命科学的持续融合，行业对高效、智能、系统化的药物研发能力提出了越来越高的要求。”

'Sanyou Bio has established a systematic strategic framework encompassing early-stage molecular discovery, R&D acceleration, and the development of an open innovation ecosystem. The company has built a solid foundation in technology platforms, collaborative R&D, and industrial resource integration. We are confident in its long-term potential to leverage AI technology to improve drug development efficiency, expand the boundaries of innovation through platform synergy, and unlock industrial value through the translation of innovative drug pipelines.'.

三友生物已建立起涵盖早期分子发现、研发加速以及开放创新生态系统建设的系统化战略框架。公司在技术平台、协同研发及产业资源整合方面奠定了坚实基础。我们对其长期潜力充满信心，相信其能够利用人工智能技术提升药物研发效率，通过平台协同效应拓展创新边界，并借助创新药物管线的转化释放产业价值。

'Through this investment, we look forward to supporting Sanyou Bio in further deepening its technological innovation and business development, and working together with the company to promote high-quality growth across the innovative drug R&D industry.'

“通过此次投资，我们期待支持三友生物进一步深化技术创新与业务发展，并与公司携手推动创新药研发行业的高质量增长。”

About Sanyou Bio

关于三友生物

Sanyou Biopharmaceuticals is a high-tech biopharmaceutical company driven by the mission of 'To make it easy to develop new drugs worldwide'. Guided by the vision 'To become a front-runner in global innovative drug R&D', the company focuses on the R&D and commercialization of innovative drugs.

三友生物制药是一家以“让全球新药研发更简单”为使命的高科技生物制药企业。公司秉持“成为全球创新药研发领跑者”的愿景，专注于创新药物的研发与商业化。

With AI-STAL, our world-leading AI-Super-Trillion Antibody Library, as our source of innovation and SAI-DA, our intelligent Sanyou AI-Drug Accelerator integrating dry-lab (in silico) and wet-lab work, as our core engine, we are building Clicklinks, an open innovation system. Driven by new drug pipelines, we accelerate the translation of innovation to benefit broad patient populations..

我们以全球领先的人工智能超级万亿抗体库（AI-STAL）为创新源泉，以整合干湿实验的智能三友AI药物加速器（SAI-DA）为核心引擎，构建“Clicklinks”开放创新体系。在新药研发管线的驱动下，我们加速创新成果转化，惠及广大患者群体。

Headquartered in Shanghai, China, with business centers established across Asia, North America, Europe, and other regions, forming a global business network, Sanyou has more than 20,000 m² of operational and planned R&D and GMP facilities.

三友总部位于中国上海，在亚洲、北美、欧洲及其他地区设有业务中心，构建了全球业务网络，拥有超过20,000平方米的运营及规划中的研发和GMP设施。

Sanyou has established strong partnerships with more than 2,000 pharmaceutical and biotechnology companies worldwide. We have signed 100+ collaborative R&D agreements. More than 10 drug candidates from these collaborations have progressed to preclinical or clinical development. We have also completed 1,000+ drug discovery and stage-specific R&D projects and delivered thousands of branded products..

三友已与全球2000多家制药和生物技术公司建立了稳固的合作伙伴关系。我们签署了100多项合作研发协议，其中超过10个药物候选分子已进入临床前或临床研究阶段。我们还完成了1000多个药物发现及分阶段研发项目，并交付了数千种品牌产品。

The company has filed more than 180 invention patent applications, with more than 30 granted. It has also obtained over 10 national and international qualifications and system certifications, including National High-Tech Enterprise, Shanghai 'Specialized and Innovative' Enterprise, ISO9001, and ISO27001..

公司已提交180多项发明专利申请，其中30多项已获得授权。公司还获得了10多项国家和国际资质及体系认证，包括国家高新技术企业、上海市“专精特新”企业、ISO9001和ISO27001认证。

About Zero2IPO Industry Investment

关于清科产业投资

Zero2IPO Industry Investment is a core business platform under Zero2IPO Group dedicated to industrial investment.

清科产业投资是清科集团旗下专注于产业投资的核心业务平台。

Since its establishment in 2012, the platform has grown to manage nearly RMB 20 billion in assets. Leveraging more than two decades of venture capital ecosystem experience accumulated by Zero2IPO Group, Zero2IPO Industry Investment remains firmly rooted in industrial development. It closely aligns its investment strategies with the diverse development needs of listed companies, family-owned enterprises, and local governments, providing customized industrial investment funds tailored to their specific requirements and connecting resources, industries, and capital across the entire value chain..

自2012年成立以来，该平台管理的资产规模已接近人民币200亿元。清科产业投资依托清科集团二十余年积累的风险投资生态系统经验，始终深耕产业发展。其投资策略紧密契合上市公司、家族企业及地方政府的多元化发展需求，提供量身定制的产业投资基金，精准对接各方特定需求，并实现资源、产业与资本在全价值链上的高效联通。

The platform currently focuses on key sectors including hard technology, new energy, healthcare, and frontier technologies.

该平台目前聚焦于硬科技、新能源、医疗健康及前沿技术等关键领域。

To date, it has invested in and supported dozens of listed companies, including Guoke Tiancheng, Injoinic, MicuRx Pharmaceuticals, Henlius, OneRobotics, Hanchorbio, Zhidian, 160 Health, Tongcheng Travel, and Suntech, as well as more than 100 high-quality growth companies and benchmark projects, including UNISOC, Pins Medical, Baibu, WehandBio, and Volant Aerotech..

迄今为止，已投资并支持了数十家上市公司，包括国科天成、英集芯、盟科药业、复宏汉霖、优必选、翰森制药、智点医疗、160健康、同程旅行和尚德电力，以及一百多家优质成长型企业和标杆项目，包括紫光展锐、品驰医疗、百布、微境生物和伏特航空。

SOURCE Sanyou Bio

来源：三友生物